盐酸帕洛诺司琼胶囊与盐酸托烷司琼治疗乳腺癌术后辅助化疗引起呕吐疗效比较

发布时间：2018-02-14 01:49

本文关键词： 乳腺癌盐酸帕洛诺司琼胶囊盐酸托烷司琼呕吐　出处：《临床军医杂志》2016年11期 　论文类型：期刊论文

【摘要】：目的探讨盐酸帕洛诺司琼胶囊与盐酸托烷司琼在预防及治疗乳腺癌患者术后行环磷酰胺联合表柔比星方案(AC方案)辅助化疗引起的恶心、呕吐等消化道反应的疗效。方法选择2012年5月至2015年4月在沈阳军区总医院肿瘤科住院的确诊为三阴性乳腺癌术后患者36例为研究对象,统一采用AC方案化疗。将36例患者随机分为A、B两组,每组各18例。A组患者化疗前30 min使用盐酸帕洛诺司琼胶囊+阿瑞匹坦+地塞米松;B组患者使用盐酸托烷司琼+阿瑞匹坦+地塞米松,以防治恶心、呕吐。比较两组患者化疗后急性呕吐及延迟性呕吐的缓解率,并观察两组患者用药后头痛、便秘、眩晕等不良反应的发生率。结果 A组总有效率为94.4%,B组总有效率为77.8%,两组总有效率比较,差异无统计学意义(P0.05)。但在急性呕吐期,A组的完全缓解率(83.3%)明显高于B组(50.0%),两组比较,差异有统计学意义(P0.05);同时,延迟期呕吐的缓解率,A组的完全缓解率(44.4%)同样高于B组(11.1%),且两组比较,差异也有统计学意义(P0.05)。在不良反应的比较中,A组便秘及胃肠道紊乱发生率低于B组,两组比较,差异有统计学意义(P0.05)。结论盐酸帕洛诺司琼胶囊在化疗相关性呕吐的治疗中,疗效明显优于盐酸托烷司琼;其不良反应的发生率也明显低于盐酸托烷司琼。
[Abstract]:Objective to investigate the effects of paronosetron hydrochloride capsule and tropisetron hydrochloride on postoperative nausea caused by cyclophosphamide combined with epirubicin (AC) regimen in the prevention and treatment of breast cancer. Methods from May 2012 to April 2015, 36 patients with triple-negative breast cancer who were hospitalized in the Department of Oncology, Shenyang military region General Hospital were selected as the study objects. 36 patients were randomly divided into two groups: group A and group B. 18 patients in group A were treated with parapisetron hydrochloride and dexamethasone hydrochloride for 30 min before chemotherapy. Group B patients received tropisetron hydrochloride and albitam dexamethasone in order to prevent and treat nausea. To compare the remission rate of acute vomiting and delayed vomiting after chemotherapy in two groups, and to observe the headache and constipation after treatment. Results the total effective rate of group A was 94.4% and the total effective rate of group B was 77.8. There was no significant difference in the total effective rate between the two groups, but the complete remission rate of group A during acute vomiting was significantly higher than that of group B (83.3%). At the same time, the complete remission rate of group A was also higher than that of group B (P 0.05), and the complete remission rate of group A was higher than that of group B (P < 0.01). The incidence of constipation and gastrointestinal disorders in group A was lower than that in group B, and the difference was statistically significant between the two groups. Conclusion Palonosetron hydrochloride capsule can be used in the treatment of chemotherapy-associated vomiting. The efficacy of tropisetron hydrochloride was better than that of tropisetron hydrochloride, and the incidence of adverse reactions was significantly lower than that of tropisetron hydrochloride.
【作者单位】：中国医科大学肿瘤医院辽宁省肿瘤医院内五科;
【分类号】：R737.9

【相似文献】